EARTH SCIENCE TECH INC (OTCMKTS:ETST) on Focus After Report of Less Shorts – Thorold News

Earth Science Tech, Inc. (OTCMKTS:ETST) Logo

The stock of EARTH SCIENCE TECH INC (OTCMKTS:ETST) registered a decrease of 27.91% in short interest. ETST’s total short interest was 3,100 shares in December as published by FINRA. Its down 27.91% from 4,300 shares, reported previously. With 50,800 shares average volume, it will take short sellers 0 days to cover their ETST’s short positions.

The stock decreased 1.14% or $0.01 during the last trading session, reaching $0.87. About 26,971 shares traded. Earth Science Tech, Inc. (OTCMKTS:ETST) has 0.00% since December 24, 2017 and is . It has by 0.00% the S&P500.

Earth Science Tech, Inc., a biotechnology company, focuses on delivering nutraceuticals, bioceuticals, and dietary supplements in the areas of health, wellness, sports, and alternative medicine worldwide. The company has market cap of $43.99 million. It focuses on non-prescription nutritional and dietary supplements for the treatment of chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea, aging, and overall wellness. It currently has negative earnings. The firm also provides consulting services to the athletic facilities industry.

More recent Earth Science Tech, Inc. (OTCMKTS:ETST) news were published by: which released: “Earth Science Tech Inc (OTCMKTS:ETST) Enters Sports Supplement Industry – WallStreetPR” on February 01, 2017. Also published the news titled: “Earth Science Tech, Inc. (ETST) Announces Strategic Partnership to Manufacture Hygeeâ„¢ Under ISO-13485 as Well as Application for New MDSAP Certification, Opening Distribution to Five Additional Countries – GlobeNewswire” on November 15, 2018.‘s news article titled: “Earth Science Tech aligns with AATAC to reach up to 90,000 retail outlets – Seeking Alpha” with publication date: June 27, 2018 was also an interesting one.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


This website uses cookies. By continuing to use this site, you accept our use of cookies.